Role of histone acetylation in the development of diabetic retinopathy and the metabolic memory phenomenon

Journal of Cellular Biochemistry

Volumn 110, Issue 6, 2010, Pages 1306-1313

  Zhong, Qing ^a   Kowluru, Renu A ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

Diabetic retinopathy; Histone acetylation; Histone deacetylase; Metabolic memory

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 8; HISTONE H3; STREPTOZOCIN;

ACETYLATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC RETINOPATHY; DISEASE COURSE; ENDOTHELIUM CELL; ENZYME ACTIVITY; GENE EXPRESSION; GLYCEMIC CONTROL; INCUBATION TIME; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; RETINA CELL;

ACETYLATION; ANIMALS; BLOTTING, WESTERN; CELLS, CULTURED; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; ENDOTHELIAL CELLS; GENE EXPRESSION; GLUCOSE; HISTONE ACETYLTRANSFERASES; HISTONE DEACETYLASES; HISTONES; MALE; PROTEIN PROCESSING, POST-TRANSLATIONAL; RATS; RATS, WISTAR; RETINA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

RATTUS;

EID: 77955498700     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.22644     Document Type: Article

References (46)

1. Berthiaume M, Boufaied N, Moisan A, Gaudreau L. 2006. High levels of oxidative stress globally inhibit gene transcription and histone acetylation. DNA Cell Biol 25:124-134.
2. Bhaumik SR, Smith E, Shilatifard A. 2007. Covalent modifications of histones during development and disease pathogenesis. Nat Struct Mol Biol 14:1008-1016.
3. Bonnefil PC, Pandozy G, Mastronardi F. 2008. Evaluating epigenetic landmarks in the brain of multiple sclerosis patients: A contribution to the current debate on disease pathogenesis. Prog Neurobiol 86:368-378.
4. Brownlee M. 2005. The pathobiology of diabetic complications: A unifying mechanism. Diabetes 54:1615-1625.
5. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. 2000. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 342:381-389.
6. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. 2008. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Arch Ophthalmol 126:1707-1715.
7. Diabetes Control and Complications Trial Research Group. 1993. The effect of intensive treatment of diabetes on the development of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986.
8. Delcuve GP, Rastegar M, Davie JR. 2009. Epigenetic control. J Cell Physiol 219:243-250.
9. Dong F, Ren J. 2007. Fidarestat improves cardiomyocyte contractile function in db/db diabetic obese mice through a histone deacetylase Sir2-dependent mechanism. J Hypertens 25:2138-2147.
10. Ellis L, Hammers H, Pili R. 2009. Targeting tumor angiogenesis with histone deacetylase inhibitors. Cancer Lett 250:145-153.
11. El-Osta A, Brasacchio D, Yao D, Pocai A, Jones PL, Roeder RG, Cooper ME, Brownlee M. 2008. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J Exp Med 205:2409-2417.
12. Endres M, Meisel A, Biniszkiewicz D, Namura S, Prass K, Ruscher K, Lipski A, Jaenisch R, Moskowitz NA, Dirnagl U. 2000. DNA methyltransferase contributes to delayed ischemic brain injury. J Neurosci 20:3175-3181.
13. Frank RN. 2004. Diabetic retinopathy. N Engl J Med 350:48-58.
14. Granger A, Abdullah I, Huebner F, Stout A, Wang T, Huebner T, Epstein JA, Gruber PJ. 2008. Histone deacetylase inhibition reduces myocardial ischemia-reperfusion injury in mice. FASEB J 22:3549-3560.
15. Haberland M, Montgomery RL, Olson EN. 2009. The many roles of histone deacetylases in development and physiology: Implications for disease and therapy. Nat Rev Genet 10:32-42.
16. Hitchler MJ, Oberley LW, Domann FE. 2008. Epigenetic silencing of SOD2 by histone modifications in human breast cancer cells. Free Radic Biol Med 45:1573-1580.
17. Howe L, Auston D, Grant P, John S, Cook RG, Workman JL, Pillus L. 2001. Histone H3 specific acetyltransferases are essential for cell cycle progression. Genes Dev 15:3144-3154.
18. Joussen AM, Huang S, Poulaki V, Camphausen K, Beecken WD, Kirchhof B, Adamis AP. 2001. In vivo retinal gene expression in early diabetes. Invest Ophthalmol Vis Sci 42:3047-3057.
19. Kang J, Chen J, Shi Y, Jia J, Zhang Y. 2005. Curcumin-induced histone hypoacetylation: The role of reactive oxygen species. Biochem Pharmacol 69:1205-1213.
20. Kanwar M, Kowluru R. 2009. Role of glyceraldehyde 3-phosphate dehydrogenase in the development and progression of diabetic retinopathy. Diabetes 58:227-234.
21. Kern TS, Tang J, Mizutani M, Kowluru R, Nagraj R, Lorenzi M. 2000. Response of capillary cell death to aminoguanidine predicts the development of retinopathy: Comparison of diabetes and galactosemia. Invest Ophthalmol Vis Sci 41:3972-3978.
22. Kowluru RA. 2003. Effect of re-institution of good glycemic control on retinal oxidative stress and nitrative stress in diabetic rats. Diabetes 52:818-823.
23. Kowluru RA. 2005a. Diabetic retinopathy, oxidative stress and antioxidants. Curr Top Nutraceutical Res 3:209-218.
24. Kowluru RA. 2005b. Diabetic retinopathy: Mitochondrial dysfunction and retinal capillary cell death. Antioxidants Redox Signal 7:1581-1587.
25. Kowluru RA, Chan PS. 2007. Oxidative stress and diabetic retinopathy. Exp Diabetes Res 2007:43603.
26. Kowluru RA, Chan PS. 2010. Metabolic memory in diabetes - From in vitro oddity to in vivo problem: Role of apoptosis. Brain Res Bull 81:297-302.
27. Kowluru RA, Kanwar M. 2009. Oxidative stress and the development of diabetic retinopathy: Contributory role of matrix metalloproteinase-2. Free Radic Biol Med 46:1677-11685.
28. Kowluru RA, Kanwar M. 2010. Inflammatory mediators in retinal microvasculature and progression of diabetic retinopathy. Exp Eye Research 90:617-623.
29. Kowluru RA, Tang J, Kern TS. 2001. Abnormalities of retinal metabolism in diabetes and experimental galactosemia. VII. Effect of long-term administration of antioxidants on the development of retinopathy. Diabetes 50:1938-1942.
30. Kowluru RA, Koppolu P, Chakrabarti S, Chen S. 2003. Diabetes-induced activation of nuclear transcriptional factor in the retina, and its inhibition by antioxidants. Free Radic Res 37:1169-1180.
31. Kowluru RA, Odenbach. 2004. Role of interleukin-1β in the development of diabetic retinopathy in rats: Effect of antioxidants. Inves Ophthal Vis Sci 45:4161-4166.
32. Kowluru RA, Kanwar M, Kennedy A. 2007. Metabolic memory phenomenon and accumulation of peroxynitrite in retinal capillaries. Exp Diabetes Res 2007:2196.
33. Lee HB, Noh H, Seo JY, Yu MR, Ha H. 2007. Histone deacetylase inhibitors: A novel class of therapeutic agents in diabetic nephropathy. Kidney Int Suppl 106:S61-S66.
34. Li AF, Roy S. 2009. High glucose-induced downregulation of connexin 43 expression promotes apoptosis in microvascular endothelial cells. Invest Ophthalmol Vis Sci 50:1400-1407.
35. Madsen-Bouterse SA, Kowluru RA. 2008. Oxidative stress and diabetic retinopathy: Pathophysiological mechanisms and treatment perspectives. Rev Endocr Metab Disord 9:315-327.
36. Madsen-Bouterse SA, Mohammad G, Kanwar M, Kowluru RA. 2010. Role of Mitochondrial DNA damage in the development of diabetic retinopathy, and the metabolic memory phenomenon associated with its progression. Antioxidants & Redox Signaling [Epub ahead of print].
37. Mizutani M, Kern TS, Lorenzi M. 1996. Accelerated death of retinal microvascular cells in human and experimental diabetic retinopathy. J Clin Invest 97:2883-2890.
38. Navaratna D, McGuire PG, Menicucci G, Das A. 2007. Proteolytic degradation of VE-cadherin alters the blood-retinal barrier in diabetes. Diabetes 56:2380-2387.
39. Noh H, Oh EY, Seo JY, Yu MR, Kim YO, Ha H, Lee HB. 2009. Histone deacetylase 2 is a key regulator of diabetes and transforming growth factor-{beta}1-induced renal injury. Am J Physiol Renal Physiol 297:F729-F739.
40. Perrone L, Devi TS, Hosoya KI, Terasaki T, Singh LP. 2009. Thioredoxin interacting protein (TXNIP) induces inflammation through chromatin modification in retinal capillary endothelial cells under diabetic conditions. J Cell Physiol 221:262-272.
41. Reddy MA, Villeneuve LM, Wang M, Lanting L, Natarajan R. 2008. Role of the lysine-specific demethylase 1 in the proinflammatory phenotype of vascular smooth muscle cells of diabetic mice. Circ Res 103:615-623.
42. Shahbazian MD, Grunstein M. 2007. Functions of site-specific histone acetylation and deacetylation. Annu Rev Biochem 76:75-100.
43. Suzuki T, Kondo S, Wakayama T, Cizdziel PE, Hayashizaki Y. 2008. Genomewide analysis of abnormal H3K9 acetylation in cloned mice. PLoS ONE 3:e1905.
44. Vaissière T, Sawan C, Herceg Z. 2008. Epigenetic interplay between histone modifications and DNA methylation in gene silencing. Mutat Res 659:40-48.
45. Villeneuve LM, Reddy MA, Lanting LL, Wang M, Meng L, Natarajan R. 2008. Epigenetic histone H3 lysine 9 methylation in metabolic memory and inflammatory phenotype of vascular smooth muscle cells in diabetes. Proc Natl Acad Sci USA 105:9047-9052.
46. Yang XJ. 2004. The diverse superfamily of lysine acetyltransferases and their roles in leukemia and other diseases. Nucleic Acid Res 32:959-976.